U.S. markets open in 50 minutes
  • S&P Futures

    +0.75 (+0.02%)
  • Dow Futures

    -15.00 (-0.04%)
  • Nasdaq Futures

    +20.75 (+0.13%)
  • Russell 2000 Futures

    -4.20 (-0.18%)
  • Crude Oil

    -0.85 (-1.02%)
  • Gold

    +13.00 (+0.73%)
  • Silver

    +0.28 (+1.18%)

    +0.0005 (+0.05%)
  • 10-Yr Bond

    -0.0100 (-0.61%)
  • Vix

    -0.73 (-4.48%)

    -0.0016 (-0.11%)

    -0.2040 (-0.18%)

    +2,031.86 (+3.26%)
  • CMC Crypto 200

    +32.44 (+2.22%)
  • FTSE 100

    +2.18 (+0.03%)
  • Nikkei 225

    +40.03 (+0.14%)

Cassava (SAVA) Posts Top-Line Data from AD Study on Simufilam

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Cassava Sciences, Inc. SAVA announced top-line data from an interim analysis of the ongoing study evaluating its drug candidate, simufilam, for treating patients with mild-to-moderate Alzheimer’s disease (“AD”).

Data from the study showed that the first 50 subjects who completed one year of open-label treatment with simufilam saw their cognition scores improve at an average of 3.2 points on Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) from the baseline. The study is being funded by the National Institutes of Health.

68% of study subjects showed improvement on ADAS-Cog and an additional 20% of the subjects showed decline of less than five points on ADAS-Cog at 12 months of treatment.

Overall, treatment with simufilam was generally well-tolerated, with no serious adverse side effect observed through the 12-month interim analysis.

Shares of Cassava have skyrocketed 667% so far this year against the industry’s decrease of 12.5%.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

In August 2021, Cassava reached an agreement with the FDA on Special Protocol Assessments (“SPA”) for its phase III studies of simufilam for the treatment of AD. The SPAs underscore the company’s alignment with the FDA on key scientific, clinical and regulatory requirements of the phase III program of simufilam in AD. The company plans to initiate the studies in the fourth quarter of 2021.

Simufilam is a proprietary, small-molecule (oral) drug that restores the normal shape and function of altered filamin A, a scaffolding protein, in the brain.

Quite a few companies are striving hard to get their AD drugs approved. Eli Lilly LLY is developing donanemab, an investigational antibody therapy, for AD. Small biotech Annovis Bio, Inc. ANVS is also developing its pipeline candidate in mid-stage study for treating AD.

The FDA approval of Biogen’s BIIB AD drug, Aduhelm (aducanumab), has put the spotlight on this promising yet challenging space. In June 2021, Biogen and its partner Eisai won the FDA approval for Aduhelm as the first and only AD treatment, after a few setbacks.

Zacks Rank

Cassava currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Biogen Inc. (BIIB) : Free Stock Analysis Report

Eli Lilly and Company (LLY) : Free Stock Analysis Report

Cassava Sciences, Inc. (SAVA) : Free Stock Analysis Report

Annovis Bio, Inc. (ANVS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research